Zacks Investment Research lowered shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a buy rating to a hold rating in a research note published on Tuesday morning.

According to Zacks, “Fresenius has had a disappointing run on the bourse over the last six months. However, a solid full-year guidance instills our confidence on the stock. We believe this is in tune with the ‘Growth Strategy 2020’, under which it aims to boost revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. A wide range of dialysis products, initiatives to gain market traction, strengthened international foothold, strategic acquisitions and divestments act as major catalysts.On the flipside, lackluster performance by the renal pharmaceutical segment is likely to dent Latin-American revenues in the coming quarters. Having a strong international foothold, Fresenius faces the brunt of stringent regulations in almost every country in which it operates. Thus, it has to fulfill specific legal requirements that include tough antitrust laws. Regulatory hurdles and competition in the niche markets are major headwinds.”

A number of other brokerages have also weighed in on FMS. SunTrust Banks set a $62.00 target price on Fresenius Medical Care AG & Co. and gave the stock a buy rating in a research note on Thursday, December 21st. Nord/LB reiterated a buy rating on shares of Fresenius Medical Care AG & Co. in a research note on Tuesday, January 2nd. DZ Bank reiterated a buy rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, November 13th. Morgan Stanley lowered Fresenius Medical Care AG & Co. from an overweight rating to an equal weight rating in a research note on Monday, December 11th. Finally, UBS Group upgraded Fresenius Medical Care AG & Co. from a sell rating to a neutral rating in a research note on Thursday, January 4th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $56.00.

Fresenius Medical Care AG & Co. (NYSE FMS) traded up $0.07 during trading hours on Tuesday, reaching $54.99. The company’s stock had a trading volume of 116,000 shares, compared to its average volume of 146,700. The company has a quick ratio of 0.98, a current ratio of 1.22 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $34,200.00, a price-to-earnings ratio of 22.08, a price-to-earnings-growth ratio of 2.27 and a beta of 0.45. Fresenius Medical Care AG & Co. has a 12-month low of $40.02 and a 12-month high of $55.30.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.02). Fresenius Medical Care AG & Co. had a net margin of 7.04% and a return on equity of 11.51%. equities research analysts forecast that Fresenius Medical Care AG & Co. will post 2.38 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. UBS Asset Management Americas Inc. increased its stake in Fresenius Medical Care AG & Co. by 3.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after acquiring an additional 81 shares during the period. YorkBridge Wealth Partners LLC increased its stake in Fresenius Medical Care AG & Co. by 19.4% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after acquiring an additional 749 shares during the period. Stifel Financial Corp bought a new position in Fresenius Medical Care AG & Co. during the 2nd quarter worth $225,000. Raymond James Financial Services Advisors Inc. bought a new position in Fresenius Medical Care AG & Co. during the 3rd quarter worth $239,000. Finally, Pacer Advisors Inc. increased its stake in Fresenius Medical Care AG & Co. by 37.6% during the 3rd quarter. Pacer Advisors Inc. now owns 5,105 shares of the company’s stock worth $250,000 after acquiring an additional 1,394 shares during the period. Hedge funds and other institutional investors own 3.03% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades Fresenius Medical Care AG & Co. (FMS) to Hold” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/zacks-investment-research-downgrades-fresenius-medical-care-ag-co-fms-to-hold/1814231.html.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.